Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.
Zhang L, Troccoli CI, Mateo-Victoriano B, Misiara Lincheta L, Jackson E, Shu P, Plastini T, Tao W, Kwon D, Chen XS, Sharma J, Jorda M, Kumar S, Lombard DB, Gulley JL, Bilusic M, Lockhart AC, Beuve A, Rai P. Zhang L, et al. Among authors: lockhart ac. Cancer Res. 2024 Oct 10. doi: 10.1158/0008-5472.CAN-24-0133. Online ahead of print. Cancer Res. 2024. PMID: 39388307
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer.
Wang J, Xiu J, Battaglin F, Arai H, Soni S, Zhang W, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astaturov I, Liu T, Lockhart AC, Korn WM, Shen L, Lenz HJ. Wang J, et al. Among authors: lockhart ac. NPJ Precis Oncol. 2024 Sep 30;8(1):214. doi: 10.1038/s41698-024-00694-8. NPJ Precis Oncol. 2024. PMID: 39349771 Free PMC article.
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.
Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG. Wang-Gillam A, et al. Among authors: lockhart ac. Clin Cancer Res. 2023 Nov 14;29(22):4698. doi: 10.1158/1078-0432.CCR-23-2993. Clin Cancer Res. 2023. PMID: 37960920 No abstract available.
The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance.
Zhang L, Troccoli CI, Mateo-Victoriano B, Lincheta LM, Jackson E, Shu P, Plastini T, Tao W, Kwon D, Chen X, Sharma J, Jorda M, Gulley JL, Bilusic M, Lockhart AC, Beuve A, Rai P. Zhang L, et al. Among authors: lockhart ac. bioRxiv [Preprint]. 2023 May 3:2023.05.03.537252. doi: 10.1101/2023.05.03.537252. bioRxiv. 2023. PMID: 37205442 Free PMC article. Preprint.
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG. Wang-Gillam A, et al. Among authors: lockhart ac. Clin Cancer Res. 2022 Dec 15;28(24):5254-5262. doi: 10.1158/1078-0432.CCR-22-0308. Clin Cancer Res. 2022. PMID: 36228156 Free PMC article. Clinical Trial.
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZA, Lunceford J, Suryawanshi S, Ayers M, J Marton M, Kato K. Shah MA, et al. Among authors: lockhart ac. Future Oncol. 2022 Jul 19. doi: 10.2217/fon-2021-1134. Online ahead of print. Future Oncol. 2022. PMID: 35852104
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, Stafford P, Spetzler D, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, El-Deiry WS, Marshall J, Shields AF, Korn WM. Philip PA, et al. Among authors: lockhart ac. Clin Cancer Res. 2022 Jun 13;28(12):2704-2714. doi: 10.1158/1078-0432.CCR-21-3581. Clin Cancer Res. 2022. PMID: 35302596 Free PMC article.
145 results